Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Asston Pharmaceuticals has informed that the Board of Directors of the Company, on the recommendation of the Audit Committee and in due compliance with the provisions of Section 175 of the Companies Act, 2013 and the rules made thereunder, has accorded its approval by way of a resolution passed by circulation for the appointment of Panchal S K and Associates (Peer Review Certificate No. 018089 and Firm Registration No. 145989W) as the Statutory Auditors of the Company, subject to the approval of the shareholders of the Company at the ensuing General Meeting. The appointment has been made after due consideration of the firm’s professional standing, eligibility, and credentials, in accordance with the applicable provisions of the Companies Act, 2013 and the rules framed thereunder. The disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as Annexure A and form an integral part of this intimation.’ In compliance with the provisions of Section 175 of the Companies Act, 2013, read with the rules made thereunder and other applicable laws for the time being in force, the delay in submission to the Exchange occurred due to the Company receiving the requisite approval of the majority of Directors on Friday, 27th February, 2026, after business hours. Thereafter, Saturday and Sunday, being non-working days, fell on 28th February, 2026, and 01st March, 2026, respectively. Accordingly, the said approval was intimated to the Exchange on the immediately succeeding working day, Monday, 02nd March, 2026. This disclosure complies with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.